What is it about?
We found that minimal inhibitory concentrations ranged between 0.125 and 1 mg/l, exerting robust antimicrobial activity against a sizeable clinical collection of the bacteria. Further, we evaluated the propensity of the methicillin-resistant Staphylococcus aureus strain MW2 to develop resistance through extended exposure to auranofin. After 25 days, the bacteria remained susceptible. Our data suggest that resistance mechanisms do not currently exist to block auranofin antimicrobial activity.
Featured Image
Why is it important?
The orphan drug auranofin was found to exhibit antimicrobial properties
Read the Original
This page is a summary of: Auranofin is an effective agent against clinical isolates of Staphylococcus aureus, Future Medicinal Chemistry, June 2019, Future Science,
DOI: 10.4155/fmc-2018-0544.
You can read the full text:
Contributors
The following have contributed to this page
